Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Akebia Therapeutics (AKBA) Reports Q4 Revenues Miss
March 18, 2019 4:12 PM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q4 revenue for the quarter came in at $59.85 million versus the consensus estimate of $73.67 million.
2018 was a transformational year for Akebia, said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. We successfully executed a number of strategic initiatives to advance our mission, and with the recent completion of our merger with Keryx, we have... More
